ISSN: 2161-0681

Revista de patología clínica y experimental

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • sherpa romeo
  • Abrir puerta J
  • Revista GenámicaBuscar
  • TOC de revistas
  • Directorio de publicaciones periódicas de Ulrich
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

Nomogram Based Survival Predictions of Patients with Soft Tissue Cancer Including Heart in the United States

Roungu Ahmmad

Introduction: This study aimed to assess the effects of cancer treatment on sarcoma types and to predict overall survival probabilities using nomograms.

Methods: This study uses the SEER-18 database, version 2020, sponsored by the National Cancer Institute (NCI). The study cohort included participants diagnosed between 2000 and 2018 with soft tissue cancers including heart. A multivariable stratified Cox proportional hazards model was applied to predict mortality rate and nomograms were used to predict overall survival probability.

Results: The median survival time for 24,849 study participants was 48 months (IQR: 19-102) with Spindle cell Sarcoma (ScS) having a shorter median survival time compared with Liposarcoma (LiS). A significant number of Soft Tissue Sarcoma (STS) patients had surgery, where surgery on ScS improved survival by 75% (HR: 0.25, 95% CI: 0.19-0.32, p<0.001) and those who received radiation had a 26% improvement (HR: 0.74, 95% CI: 0.61-0.89, p=0.001). Furthermore, chemotherapy on GcS resulted in a 40% reduction in mortality for patients compared to those who did not receive chemotherapy (HR: 0.60, 95% CI: 0.45-0.80, p<0.001). Based on nomogram, after two, five and ten years, a patient who received surgery on their primary sites would have a survival rate of approximately 90%. In contrast, a patient who did not receive surgery on their primary sites would only live for 20% or less. Patients with MyS have a 90% chance of surviving for 5 and 10 years after surgical intervention, but only 22% and 10% without surgery.

Conclusion: Based on the results of this study, surgical and radiation intervention was associated with improved survival in patients with STS, while chemotherapy and primary systemic therapy had contradictory effects.